Mekonos Enters Partnership Agreement with Accelerated Biosciences to Develop and Commercialize Engineered Human Trophoblast Stem Cells (hTSCs) for Biomanufacturing
Mekonos, Inc. , a biotech platform company building the future of cell engineering on a chip, today announced it has entered into a partnership agreement with Accelerated Biosciences Corp. (“Accelerated Bio”) to codevelop a powerful, new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.
- Mekonos, Inc. , a biotech platform company building the future of cell engineering on a chip, today announced it has entered into a partnership agreement with Accelerated Biosciences Corp. (“Accelerated Bio”) to codevelop a powerful, new manufacturing cell line based on Accelerated Bio’s human Trophoblast Stem Cells (hTSCs) and Gene Engineered Multi-Sites (GEMS) technology.
- The hTSC platform is the earliest ethically sourced pluripotent stem cells that are naive, powerful, lively and have high plasticity.
- These limitations compound and can cause cell functionality compromises and performance issues downstream, given the lack of consistency in engineered cells and inefficient scale-up.
- Mekonos recognizes there is a better way, and we are rising to the challenge,” Narasimha added.